Skip to main content
Premium Trial:

Request an Annual Quote

Meridian's Group B Streptococcus Test Approved for Sale in Australia

NEW YORK (GenomeWeb News) – Meridian Bioscience's wholly owned subsidiary Bioline announced today that its illumigene Group B Streptococcus test has received regulatory approval for commercialization in Australia.

Clearance from the Therapeutic Goods Administration follows similar action in the US by the Food and Drug Administration.

The test is based on loop-mediated isothermal DNA amplification technology and detects Streptococcus agalactiae from enriched cultures from vaginal swabs. Results can be achieved in less than an hour, Meridian said, adding that GBS remains a major prenatal pathogen and is associated with significant morbidity and mortality in infants.

"illumigene GBS is a key addition to the illumigene platform given the importance of early detection of GBS to prevent serious disease in infants," Richard Eberly, COO of Meridian, said in a statement. "This new test begins the expansion of the illumigene platform and provides a molecular technology that is affordable, simple, and quick."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.